ZURA
Zura Bio Limited
Price Chart
No historical data available
Latest Quote
$5.61
| Previous Close | $5.85 |
| Open | $5.80 |
| Day High | $5.85 |
| Day Low | $5.49 |
| Volume | 785,969 |
Stock Information
| Shares Outstanding | 95.83M |
| Cash Equivalents | $205.13M |
| Net Income | $-116.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $548.14M |
| EPS (TTM) | $-1.10 |
| Exchange | NCM |
Recent Price History
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
đ° Latest News
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $75,246,000 | $55,189,000 | $62,638,000 | $27,162,000 |
| Other Income Expense | $260,000 | $-5,212,000 | $-111,000 | $-179,000 |
| Other Non Operating Income Expenses | $260,000 | $28,000 | $-2,227,000 | $-179,000 |
| Net Non Operating Interest Income Expense | $6,336,000 | $7,998,000 | $2,186,000 | $8,000 |
| Operating Expense | $75,246,000 | $55,189,000 | $62,638,000 | $27,162,000 |
| General And Administrative Expense | $33,164,000 | $30,788,000 | $18,639,000 | $3,473,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-68,650,000 | $-52,403,000 | $-60,360,000 | $-25,738,000 |
| Net Interest Income | $6,336,000 | $7,998,000 | $2,186,000 | $8,000 |
| Interest Income | $6,336,000 | $7,998,000 | $2,186,000 | $8,000 |
| Normalized Income | $-68,650,000 | $-47,163,000 | $-62,476,000 | $-25,738,000 |
| Net Income From Continuing And Discontinued Operation | $-68,650,000 | $-52,403,000 | $-60,360,000 | $-25,738,000 |
| Total Operating Income As Reported | $-75,246,000 | $-55,189,000 | $-62,638,000 | $-27,162,000 |
| Net Income Common Stockholders | $-99,353,000 | $-45,386,000 | $-69,243,000 | $-32,390,000 |
| Net Income | $-68,650,000 | $-52,403,000 | $-60,360,000 | $-25,738,000 |
| Net Income Including Noncontrolling Interests | $-68,650,000 | $-52,403,000 | $-60,563,000 | $-27,333,000 |
| Net Income Continuous Operations | $-68,650,000 | $-52,403,000 | $-60,563,000 | $-27,333,000 |
| Pretax Income | $-68,650,000 | $-52,403,000 | $-60,563,000 | $-27,333,000 |
| Interest Income Non Operating | $6,336,000 | $7,998,000 | $2,186,000 | $8,000 |
| Operating Income | $-75,246,000 | $-55,189,000 | $-62,638,000 | $-27,162,000 |
| Per Share | ||||
| Diluted EPS | $-1.06 | $-0.60 | $-2.09 | $-12.19 |
| Basic EPS | $-1.06 | $-0.60 | $-2.09 | $-12.19 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-75,197,000 | $-49,940,000 | $-64,754,000 | $-27,162,000 |
| Reconciled Depreciation | $49,000 | $9,000 | $0 | - |
| EBITDA (Bullshit earnings) | $-75,197,000 | $-55,180,000 | $-62,638,000 | $-27,162,000 |
| EBIT | $-75,246,000 | $-55,189,000 | $-62,638,000 | $-27,162,000 |
| Diluted Average Shares | $94,160,138 | $75,070,761 | $33,064,036 | $2,111,000 |
| Basic Average Shares | $94,160,138 | $75,070,761 | $33,064,036 | $2,111,000 |
| Diluted NI Availto Com Stockholders | $-99,353,000 | $-45,386,000 | $-69,243,000 | $-32,390,000 |
| Otherunder Preferred Stock Dividend | $30,703,000 | $-7,017,000 | $8,883,000 | $6,652,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Research And Development | $42,082,000 | $24,401,000 | $43,999,000 | $23,689,000 |
| Selling General And Administration | $33,164,000 | $30,788,000 | $18,639,000 | $3,473,000 |
| Other Gand A | $33,164,000 | $30,788,000 | $18,639,000 | $3,473,000 |
| Total Unusual Items | - | $-5,240,000 | $2,116,000 | $6,223,698 |
| Total Unusual Items Excluding Goodwill | - | $-5,240,000 | $2,116,000 | $6,223,698 |
| Minority Interests | - | $0 | $203,000 | $1,595,000 |
| Gain On Sale Of Security | - | $-5,240,000 | $2,116,000 | $6,223,698 |
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $101,538,000 | $146,815,000 | $59,330,000 | $-32,056,000 |
| Total Assets | $113,948,000 | $179,533,000 | $100,843,000 | $5,262,000 |
| Total Non Current Assets | $1,638,000 | $789,000 | $0 | $3,486,000 |
| Other Non Current Assets | $1,512,000 | $698,000 | - | $141,474,352 |
| Current Assets | $112,310,000 | $178,744,000 | $100,843,000 | $1,776,000 |
| Other Current Assets | $2,903,000 | $2,246,000 | $1,037,000 | $209,000 |
| Cash Cash Equivalents And Short Term Investments | $109,407,000 | $176,498,000 | $99,806,000 | $1,567,000 |
| Cash And Cash Equivalents | $109,407,000 | $176,498,000 | $99,806,000 | $1,567,000 |
| Non Current Deferred Assets | - | - | $0 | $3,486,000 |
| Cash Equivalents | - | - | $97,913,000 | - |
| Cash Financial | - | - | $1,893,000 | $13,785 |
| Prepaid Assets | - | - | - | $19,702 |
| Debt | ||||
| Net Debt | - | - | - | $6,189,000 |
| Total Debt | - | - | - | $7,756,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $7,756,000 |
| Current Debt | - | - | - | $7,756,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,410,000 | $19,514,000 | $21,292,000 | $27,318,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $990,000 | $12,500,000 |
| Current Liabilities | $12,410,000 | $19,514,000 | $20,302,000 | $14,818,000 |
| Payables And Accrued Expenses | $9,091,000 | $17,801,000 | $19,101,000 | $4,287,000 |
| Payables | $1,279,000 | $733,000 | $2,749,000 | $2,010,000 |
| Accounts Payable | $1,279,000 | $733,000 | $2,749,000 | $2,010,000 |
| Derivative Product Liabilities | - | $0 | $990,000 | $0 |
| Current Notes Payable | - | - | $0 | $7,756,000 |
| Non Current Deferred Liabilities | - | - | - | $4,010,000 |
| Other Current Liabilities | - | - | - | $2,634,000 |
| Equity | ||||
| Common Stock Equity | $101,538,000 | $146,815,000 | $59,330,000 | $-32,056,000 |
| Total Equity Gross Minority Interest | $101,538,000 | $160,019,000 | $79,551,000 | $-22,056,000 |
| Stockholders Equity | $101,538,000 | $146,815,000 | $59,330,000 | $-32,056,000 |
| Retained Earnings | $-224,547,000 | $-155,897,000 | $-103,494,000 | $-32,056,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $12,500,000 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $73,680,710 | $65,297,530 | $43,593,678 | $27,052,155 |
| Share Issued | $73,680,710 | $65,297,530 | $43,593,678 | $27,052,155 |
| Tangible Book Value | $101,538,000 | $146,815,000 | $59,330,000 | $-32,056,000 |
| Invested Capital | $101,538,000 | $146,815,000 | $59,330,000 | $-24,300,000 |
| Working Capital | $99,900,000 | $159,230,000 | $80,541,000 | $-13,042,000 |
| Total Capitalization | $101,538,000 | $146,815,000 | $59,330,000 | $-32,056,000 |
| Minority Interest | $0 | $13,204,000 | $20,221,000 | $10,000,000 |
| Additional Paid In Capital | $326,078,000 | $302,705,000 | $162,820,000 | $0 |
| Capital Stock | $7,000 | $7,000 | $4,000 | $0 |
| Common Stock | $7,000 | $7,000 | $4,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,319,000 | $1,713,000 | $1,201,000 | $141,000 |
| Current Accrued Expenses | $7,812,000 | $17,068,000 | $16,352,000 | $2,277,000 |
| Net PPE | $126,000 | $91,000 | $0 | - |
| Preferred Stock | - | $0 | $0 | $0 |
| Dueto Related Parties Current | - | - | - | $78,893 |
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-64,928,000 | $-33,151,000 | $-23,054,000 | $-13,202,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-64,815,000 | $-28,076,000 | $-15,054,000 | $-1,202,000 |
| Cash Flow From Continuing Operating Activities | $-64,815,000 | $-28,076,000 | $-15,054,000 | $-1,202,000 |
| Operating Gains Losses | $-4,916,000 | $5,213,000 | $-741,000 | $23,000 |
| Investing Activities | ||||
| Capital Expenditure | $-113,000 | $-5,075,000 | $-8,000,000 | $-12,000,000 |
| Investing Cash Flow | $-113,000 | $-5,075,000 | $-8,000,000 | $-12,000,000 |
| Cash Flow From Continuing Investing Activities | $-113,000 | $-5,075,000 | $-8,000,000 | $-12,000,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,096,000 | $60,757,000 | $116,407,000 | $10,000,000 |
| Financing Cash Flow | $-2,163,000 | $109,843,000 | $121,293,000 | $14,769,000 |
| Cash Flow From Continuing Financing Activities | $-2,163,000 | $109,843,000 | $121,293,000 | $14,769,000 |
| Net Other Financing Charges | $-7,366,000 | $-944,000 | $-1,184,000 | $-2,831,000 |
| Net Common Stock Issuance | $5,096,000 | $60,757,000 | $116,407,000 | $0 |
| Common Stock Issuance | $5,096,000 | $60,757,000 | $116,407,000 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $10,000,000 |
| Preferred Stock Issuance | - | - | $0 | $10,000,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $109,407,000 | $176,498,000 | $99,806,000 | $1,567,000 |
| Beginning Cash Position | $176,498,000 | $99,806,000 | $1,567,000 | $0 |
| Changes In Cash | $-67,091,000 | $76,692,000 | $98,239,000 | $1,567,000 |
| Proceeds From Stock Option Exercised | $107,000 | $50,030,000 | $16,070,000 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-5,000,000 | $-8,000,000 | $-12,000,000 |
| Purchase Of Intangibles | $0 | $-5,000,000 | $-8,000,000 | $-12,000,000 |
| Net PPE Purchase And Sale | $-113,000 | $-75,000 | $0 | - |
| Purchase Of PPE | $-113,000 | $-75,000 | $0 | - |
| Change In Working Capital | $-3,634,000 | $2,307,000 | $5,116,000 | $3,541,000 |
| Change In Other Current Assets | $-814,000 | $-698,000 | $0 | - |
| Change In Payables And Accrued Expense | $-2,163,000 | $4,214,000 | $5,944,000 | $3,750,000 |
| Change In Prepaid Assets | $-657,000 | $-1,209,000 | $-828,000 | $-209,000 |
| Other Non Cash Items | $4,000 | - | $29,235,000 | $22,077,000 |
| Stock Based Compensation | $12,332,000 | $16,798,000 | $9,655,000 | $334,000 |
| Depreciation Amortization Depletion | $49,000 | $9,000 | $0 | - |
| Depreciation And Amortization | $49,000 | $9,000 | $0 | - |
| Net Foreign Currency Exchange Gain Loss | $84,000 | $-27,000 | $-17,000 | $23,000 |
| Net Income From Continuing Operations | $-68,650,000 | $-52,403,000 | $-60,563,000 | $-27,333,000 |
| Repayment Of Debt | - | $0 | $-10,000,000 | $0 |
| Net Issuance Payments Of Debt | - | $0 | $-10,000,000 | $7,600,000 |
| Net Short Term Debt Issuance | - | $0 | $-10,000,000 | $7,600,000 |
| Short Term Debt Payments | - | $0 | $-10,000,000 | $0 |
| Unrealized Gain Loss On Investment Securities | - | $0 | $2,244,000 | $156,000 |
| Gain Loss On Investment Securities | - | $5,240,000 | $-724,000 | $-6,223,698 |
| Issuance Of Debt | - | - | $0 | $7,600,000 |
| Short Term Debt Issuance | - | - | $0 | $7,600,000 |
| Net Long Term Debt Issuance | - | - | $-10,000,000 | $0 |
| Long Term Debt Payments | - | - | $-10,000,000 | $0 |
| Change In Accrued Expense | - | - | - | $912,053 |
| Change In Payable | - | - | - | $288,293 |
| Change In Account Payable | - | - | - | $288,293 |
| Change In Receivables | - | - | - | $0 |